An Open-Label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-Release to Extended-Release Formulation and Vice Versa

Trial Profile

An Open-Label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-Release to Extended-Release Formulation and Vice Versa

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jan 2018

At a glance

  • Drugs Lamotrigine (Primary)
  • Indications Epilepsy
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 23 Jan 2018 Results assessing the effect of Age-Related Factors on the PK of Lamotrigine and Potential Implications for Dose Optimisation in patients data obtained from NCT00043875, NCT00144872, NCT00113165, NCT00104416, NCT00516139, NCT00264615 published in the Clinical Pharmacokinetics
    • 15 Oct 2008 Actual start date changed from Aug 2005 to Oct 2005 as reported by clinicalTrials.gov.
    • 14 Oct 2008 Trial phase changed from II/III to III as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top